Quantity restrictions increasingly prevalent in pharma patent settlements, US FTC finds
MLex Summary: US Federal Trade Commission staff published four reports covering fiscal years 2018, 2019, 2020, and 2021 on the types and terms of the pharmaceutical patent settlement agreements filed with...To view the full article, register now.
Already a subscriber? Click here to view full article